Actively Recruiting
Respiratory Syncytial Virus Infection in Exacerbations of Chronic Obstructive Pulmonary Diasease: the RECODE Study
Led by Fundacio Privada Mon Clinic Barcelona · Updated on 2025-02-26
892
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are examining the presence of respiratory syncytial virus (RSV) infection in adults aged 50 and older who have chronic obstructive pulmonary disease (COPD) and experience worsening symptoms during the RSV season from October to April. This observational study aims to find out how common RSV infection is among these patients and whether it leads to more severe outcomes like hospitalization, longer hospital stays, heart problems, or death. The study compares patients who test positive for RSV with those who do not to understand the impact of the virus on COPD exacerbations. Participants will receive standard medical care for COPD exacerbations, including long-acting bronchodilators and inhaled corticosteroids, and may take antibiotics or oral corticosteroids if needed during their hospital stay. Diagnostic testing for RSV infection is done as part of routine care during their visit to the emergency department or day hospital. The study observes two groups based on whether their exacerbations occur during or outside the RSV season. Throughout the study, participants will provide demographic and clinical information like medical history, COPD severity, other health conditions, and past exacerbation events. Researchers will monitor key outcomes such as hospitalization rates, length of hospital stay, acute cardiovascular events, and mortality during the exacerbation period. The main measurement is the prevalence of RSV infection during COPD exacerbations in the RSV season, tracked over one year.
CONDITIONS
Brief Title
Respiratory Syncytial Virus Infection in Exacerbations of Chronic Obstructive Pulmonary Diasease: the RECODE Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female or male
- 50 years of age or older
- Seeking urgent medical attention due to acute exacerbation of COPD defined by worsening dyspnea and/or cough and sputum over less than 14 days, possibly with rapid breathing or heart rate, often linked to airway infection or other airway insults
You will not qualify if you...
- Previous vaccination against respiratory syncytial virus (RSV)
- Active cancer or other diseases that affect immune status
- Neurologic disorders that prevent participation
- Not signing the informed consent form
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 14 days
Participants experiencing acute exacerbations of COPD during or outside the RSV season are evaluated to determine RSV infection status.
1 to 2 visits depending on symptom severity
Duration - Up to 1 year
Participants are observed over the RSV season to determine the prevalence of RSV infection related to exacerbations of COPD.
Periodic visits during the RSV season
Trial Site Locations
Total: 1 location
1
Hospital Clínic de Barcelona
Barcelona, Spain
Actively Recruiting
Research Team
M
Maria Garcia
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here